Intensity Therapeutics (INTS) H.C. Wainwright 28th Annual Global Investment Conference summary

Conference overview

• Over 500 companies presented across life sciences, cryptocurrency, technology, media, and telecommunications sectors.

• The event featured one-on-one meetings, corporate presentations, and expert panels.

Technology and clinical development

• A novel cancer therapy induces immunogenic cell death using a supramolecular complex for intratumoral injection.

• The technology is stable for up to four years and leverages a delivery mechanism similar to that used in the Wegovy pill.

• Over 200 patients have been treated in two completed clinical trials, with ongoing phase III and phase II studies in metastatic sarcoma and pre-surgical breast cancer.

Clinical trial results and endpoints

• Phase III sarcoma trial targets overall survival, with interim analyses at 20%, 40%, and 60% enrollment.

• Phase II breast cancer trial aims for pathological complete response, showing a trend toward improved outcomes and reduced adverse events.

• Early data indicate a 20% abscopal effect, with uninjected tumors shrinking and median survival extended to 21 months in some cohorts.